AbbVie stock has fallen 10.6% YTD despite strong long-term gains; a popular view sees it ~17.7% undervalued with a $249 fair value driven by immunology growth, yet an 86.7x P/E suggests growth is priced in and could face shocks if execution falters.

NodeGuardian

2026-04-22 05:47:29

Abstract generation in progress

AbbVie (ABBV) has seen its share price soften recently, declining 10.55% year-to-date, despite strong longer-term returns. A popular valuation narrative suggests the company is 17.7% undervalued with a fair value of $249.14, driven by growth in its immunology portfolio. However, its high P/E ratio of 86.7x (compared to industry averages) indicates that future earnings growth might already be priced in, posing risks if execution falters.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
930.6K Popularity
#
WCTCTradingChallengeShare8MUSDT
758.07K Popularity
#
BitcoinBouncesBack
194.35K Popularity
#
USIranTalksProgress
565.56K Popularity
#
ArbitrumFreezesKelpDAOHackerETH
22.17K Popularity

Sitemap

Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Lofty P/E Premium

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

BitcoinBouncesBack

USIranTalksProgress

ArbitrumFreezesKelpDAOHackerETH

Pin